Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0S4JK
|
||||
Former ID |
DCL000170
|
||||
Drug Name |
MLN8237
|
||||
Synonyms |
Alisertib
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Anticancer Agents
|
||||
Structure |
Download2D MOL |
||||
Formula |
C27H20ClFN4O4
|
||||
InChI |
InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
|
||||
InChIKey |
ZLHFILGSQDJULK-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
49693830, 57107096, 99436914, 103651972, 103905632, 104120110, 123055410, 124757022, 125163826, 131477692, 131480698, 134223405, 134338845, 135263892, 135626804, 135727405, 136367323, 136920350, 137173580, 137276087, 141669651, 143499693, 144116244, 152064066, 152234949, 152258281, 152344273, 160647120, 160838255, 162011658, 162037455, 162202572, 163098799, 163403893, 164193986, 164339418, 172095365, 172918135, 174006392, 174525840, 180111921, 185998541, 188899555, 198972240, 198993425, 204398557, 223366121, 223382037, 223613049, 223705104
|
||||
Target and Pathway | |||||
Target(s) | Aurora kinase A | Target Info | Inhibitor | [549980] | |
KEGG Pathway | Oocyte meiosis | ||||
Pathway Interaction Database | Aurora B signaling | ||||
Signaling by Aurora kinases | |||||
Integrin-linked kinase signaling | |||||
PLK1 signaling events | |||||
Aurora A signaling | |||||
References | |||||
Ref 523707 | ClinicalTrials.gov (NCT01482962) Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma. U.S. National Institutes of Health. | ||||
Ref 542741 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7790). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.